Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
2.
Genet Med ; 17(12): 995-1001, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25790160

RESUMO

PURPOSE: The Scripps Idiopathic Diseases of Man (IDIOM) study aims to discover novel gene-disease relationships and provide molecular genetic diagnosis and treatment guidance for individuals with novel diseases using genome sequencing integrated with clinical assessment and multidisciplinary case review. Here we describe the operational protocol and initial results of the IDIOM study. METHODS: A total of 121 cases underwent first-tier review by the principal investigators to determine whether the primary inclusion criteria were satisfied, 59 (48.8%) underwent second-tier review by our clinician-scientist review panel, and 17 patients (14.0%) and their family members were enrolled. RESULTS: 60% of cases resulted in a plausible molecular diagnosis, and 18% of cases resulted in a confirmed molecular diagnosis. Two of three confirmed cases led to the identification of novel gene-disease relationships. In the third confirmed case a previously described but unrecognized disease was revealed. In all three confirmed cases a new clinical management strategy was initiated based on the genetic findings. CONCLUSION: Genome sequencing provides tangible clinical benefit for individuals with idiopathic genetic disease, not only in the context of molecular genetic diagnosis of known rare conditions but also in cases where prior clinical information regarding a new genetic disorder is lacking.


Assuntos
Doenças Genéticas Inatas/diagnóstico , Genoma Humano , Patologia Molecular , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Doenças Genéticas Inatas/terapia , Genômica , Humanos , Lactente , Masculino , Doenças Raras/diagnóstico , Doenças Raras/genética , Doenças Raras/terapia , Análise de Sequência de DNA , Adulto Jovem
3.
Clin Immunol ; 155(1): 126-135, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25236785

RESUMO

Group 2 innate lymphoid cells (ILC2s) have recently been identified in human nasal polyps, but whether numbers of ILC2s differ by polyp endotype or are influenced by corticosteroid use is unknown. Here, we show that eosinophilic nasal polyps contained double the number of ILC2s vs. non-eosinophilic polyps. Polyp ILC2s were also reduced by 50% in patients treated with systemic corticosteroids. Further, using a fungal allergen challenge mouse model, we detected greatly reduced Th2 cytokine-producing and Ki-67+ proliferating lung ILC2s in mice receiving dexamethasone. Finally, ILC2 Annexin V staining revealed extensive apoptosis after corticosteroid treatment in vivo and in vitro. Thus, ILC2s are elevated in the eosinophilic nasal polyp endotype and systemic corticosteroid treatment correlated with reduced polyp ILC2s. Finally, allergen-challenged mice showed reduced ILC2s and increased ILC2 apoptosis after corticosteroid treatment suggesting that ILC2 may be responsive to corticosteroids in eosinophilic respiratory disease.


Assuntos
Dexametasona/farmacologia , Linfócitos/classificação , Metilprednisolona/farmacologia , Pólipos Nasais/patologia , Prednisona/farmacologia , Adulto , Animais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/farmacologia , Dexametasona/administração & dosagem , Feminino , Humanos , Masculino , Metilprednisolona/administração & dosagem , Camundongos , Pólipos Nasais/genética , Prednisona/administração & dosagem , Adulto Jovem
4.
Hematol Oncol Clin North Am ; 20(5): 1023-49, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16990105

RESUMO

The pathology of HCL has been reviewed with a focus on the diagnostic hematopathology of this rare, but fascinating, disease. The discrimination of HCL from other B-cell lymphoproliferations, particularly HCL-V and SMZL, has been emphasized. The unique responsiveness of HCL to 2-CdA and other chemotherapeutic agents makes this distinction critical. Fortunately, HCL has consistent cytologic, histologic, cytochemical, and immunologic features that make classification reliable and reproducible. Less straightforward is the differential diagnosis of SMZL and HCL-V, problematic because of the rarity of both disorders, lack of discriminating evidence-based criteria, and perhaps a biologic kinship between these two disorders that share many clinical and pathologic features. Fortunately, this is not a clinically critical distinction.


Assuntos
Antígenos de Neoplasias/imunologia , Biomarcadores Tumorais/imunologia , Leucemia de Células Pilosas/imunologia , Leucemia de Células Pilosas/patologia , Antígenos de Neoplasias/sangue , Biomarcadores Tumorais/sangue , Medula Óssea/imunologia , Medula Óssea/metabolismo , Medula Óssea/patologia , Diagnóstico Diferencial , Citometria de Fluxo/métodos , Humanos , Leucemia de Células Pilosas/sangue , Linfonodos/imunologia , Linfonodos/metabolismo , Linfonodos/patologia , Linfoma de Células B/sangue , Linfoma de Células B/imunologia , Linfoma de Células B/patologia , Linfoma não Hodgkin/sangue , Linfoma não Hodgkin/imunologia , Linfoma não Hodgkin/patologia , Baço/imunologia , Baço/metabolismo , Baço/patologia
5.
Best Pract Res Clin Haematol ; 16(1): 15-31, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12670462

RESUMO

Hairy-cell leukaemia (HCL) is a low grade B-cell lymphoproliferative process that presents either with lymphocytosis or neutropenia/monocytopenia. It is a disease predominantly of bone marrow and spleen, although it can also involve other organs and sites. Recent advances including multi-parameter flow cytometry and the development of antibodies with high specificity for HCL have permitted precise distinction of typical HCL from other lymphoproliferative diseases that can morphologically mimic the appearance of HCL. Although there is a commonly held belief that HCL is associated with a significant increase in second neoplasms, several recent studies have not supported this notion. The development of extremely effective therapy for HCL results in a high incidence of complete remission. However, a significant percentage of patients continue to harbour minimal residual disease that can be revealed with immunohistochemical and flow cytometric studies.


Assuntos
Leucemia de Células Pilosas/patologia , Antineoplásicos/uso terapêutico , Transformação Celular Neoplásica/imunologia , Transformação Celular Neoplásica/patologia , Citometria de Fluxo/métodos , Humanos , Imuno-Histoquímica/métodos , Interferon-alfa/uso terapêutico , Leucemia de Células Pilosas/tratamento farmacológico , Leucemia de Células Pilosas/imunologia
6.
Sci Rep ; 3: 1449, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23618955

RESUMO

To investigate the transition from non-cancerous to metastatic from a physical sciences perspective, the Physical Sciences-Oncology Centers (PS-OC) Network performed molecular and biophysical comparative studies of the non-tumorigenic MCF-10A and metastatic MDA-MB-231 breast epithelial cell lines, commonly used as models of cancer metastasis. Experiments were performed in 20 laboratories from 12 PS-OCs. Each laboratory was supplied with identical aliquots and common reagents and culture protocols. Analyses of these measurements revealed dramatic differences in their mechanics, migration, adhesion, oxygen response, and proteomic profiles. Model-based multi-omics approaches identified key differences between these cells' regulatory networks involved in morphology and survival. These results provide a multifaceted description of cellular parameters of two widely used cell lines and demonstrate the value of the PS-OC Network approach for integration of diverse experimental observations to elucidate the phenotypes associated with cancer metastasis.


Assuntos
Biomarcadores Tumorais/metabolismo , Regulação Neoplásica da Expressão Gênica , Modelos Biológicos , Metástase Neoplásica/patologia , Metástase Neoplásica/fisiopatologia , Proteínas de Neoplasias/metabolismo , Linhagem Celular Tumoral , Movimento Celular , Tamanho Celular , Sobrevivência Celular , Simulação por Computador , Humanos
7.
Curr Opin Hematol ; 10(4): 258-66, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12799530

RESUMO

Hairy cell leukemia is an indolent, chronic B-cell lymphoproliferative disorder comprising approximately 2 to 3% of all adult leukemias in the United States. Hairy cells are clonal expansions of mature, activated B-cells. They co-express CD11c, CD19, CD20, CD22, CD25, and CD103. Hairy cells possess clonal immunoglobulin gene rearrangements and express monoclonal surface immunoglobulin of either IgG or multiple heavy-chain isotypes. Treatment of hairy cell leukemia should be considered for symptomatic patients. It is indicated in patients with significant neutropenia, anemia, thrombocytopenia, symptomatic splenomegaly, constitutional symptoms due to hairy cell leukemia, or recurrent serious infections. Many treatments exist, including cladribine, pentostatin, interferon-alpha, splenectomy, rituximab (mabthera), and BL-22 immunotoxin.


Assuntos
Leucemia de Células Pilosas/patologia , Leucemia de Células Pilosas/terapia , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Linhagem da Célula , Humanos , Imunofenotipagem , Resultado do Tratamento
8.
Am J Hematol ; 74(4): 227-30, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14635201

RESUMO

Hairy cell leukemia (HCL) is a rare chronic B-cell lymphoproliferative disorder characterized by splenomegaly, pancytopenia, and circulating atypical lymphocytes with circumferential cytoplasmic projections. Although uncommon, HCL cases refractory to standard therapy occur, and effective alternatives are limited. There is evolving literature supporting monoclonal antibody therapy in the treatment of B-cell lymphoid malignancies, including anti-CD52 (Campath-1H, alemtuzumab). We have examined nine cases of HCL and one case of HCL variant by flow cytometry for CD52 expression. All cases expressed CD52 antigen in 92-100% of the malignant cells. The demonstration of CD52 antigen expression on HCL cells provides the rationale for the use of alemtuzumab in refractory HCL.


Assuntos
Antígenos CD/análise , Antígenos de Neoplasias/análise , Glicoproteínas/análise , Leucemia de Células Pilosas/patologia , Adulto , Idoso , Alemtuzumab , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Anticorpos Antineoplásicos/uso terapêutico , Células da Medula Óssea/imunologia , Antígeno CD52 , Estudos de Coortes , Citometria de Fluxo , Humanos , Imunofenotipagem , Leucemia de Células Pilosas/tratamento farmacológico , Leucócitos/imunologia , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa